TABLE 1.
Characteristics of studies included in the meta-analysis1
| Study (reference), country | Consortium | Treatment regimens | Study dates | Type of ALL (participants, n) | Age at diagnosis, y | Anthropometric data collection2 | Definition of weight category |
| ALL (n = 7) | |||||||
| Aldhafiri (10), United Kingdom | MRC | UKALL-X | 1985–1990 | “Standard Risk” ALL (1033) | 2.0–14.9 | Prospectively on clinical trial | BMI (international norms)3 |
| Baillargeon (11), United States | POG | “HR and SR regimens” | 1990–2002 | SR and HR BP-ALL (322) | 2–18 | Retrospective review of medical records | BMI (CDC) |
| Butturini (7),4 United States | CCG/COG | CCG1881, CCG1992, CCG1891, CCG1882, CCG1901 | 1988–1995 | SR and HR BP-ALL, T-ALL (4260) | 2.00–19.99 | Prospectively on clinical trial | BMI (CDC) |
| Ethier (12), Canada | POG/COG | AALL0232, AALL0331, POG9904, POG9905, A5971 | 2001–2006 | SR and HR BP-ALL, T-ALL (238) | 2.1–17.8 | Retrospective review of medical records | BMI (CDC) |
| Hijiya (9), United States | SJRC | Total XII, XIIIA, XIIIB, XIV | 1988–2000 | SR and HR BP-ALL, T-ALL (621) | 1.01–18.80 | Prospectively on clinical trial | Age <2y: WFL (CDC) Age ≥2y: BMI (CDC) |
| Orgel (13), United States | CCG/COG | CCG1961 | 1996–2002 | HR BP-ALL (2008) | 1–20 | Prospectively on clinical trial | Age <2y: WFL (CDC) Age ≥2y: BMI (CDC) |
| Orgel (14), United States | CCG/COG | CCG1991, CCG1961, AALL0331, AALL0932, AALL08P1, AALL0232, AALL1131 | 2008–2013 | SR and HR BP-ALL (198) | 1–21 | Retrospective review of medical records | Age <2y: WFL (CDC) Age ≥2y: BMI (CDC) |
| Niinimaki (15), Finland | NSPHO | ALL-NSPHO 86, 92, 2000 | 1992–2005 | NSPHO-defined risk category (97) | 1–15 | Cross-sectional analysis of survivors | BMI (Finnish norms) |
| AML (n = 3) | |||||||
| Canner (16), United States | CCG/COG | CCG2891, CCG2941, CCG2961, AAML03P1 | 1989–2006 | de novo AML (1840) | 0.01–20.9 | Prospectively on clinical trial | Age <2y: WFL (CDC) Age ≥2y: BMI (CDC) |
| Inaba (17), United States | SJRC | AML87, AML91, AML9, AML02 | 1987–2008 | de novo AML (314) | 2.0–19.9 | Prospectively on clinical trial | BMI (CDC) |
| Lange (18), United States | CCG/COG | CCG2961 | 1996–2002 | de novo AML (768) | 0.01–20.9 | Prospectively on clinical trial | BMI (CDC) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BP-ALL, B-precursor acute lymphoblastic leukemia; CCG, Children’s Cancer Group; COG, Children’s Oncology Group; HR, National Cancer Institute/Rome high risk; MRC, Medical Research Council; NSPHO, Nordic Society of Pediatric Haematology and Oncology; POG, Pediatric Oncology Group; SJRC, St. Jude Research Consortium; SR, National Cancer Institute/Rome standard risk; T-ALL, T cell acute lymphoblastic leukemia; WFL, weight-for-length.
All heights and weights were obtained by clinical measurement.
Thresholds for underweight, normal, overweight, and obesity as used in this study were drawn from a previously reported 6-country international survey.
Excludes the verification cohort of CCG-1961 included separately.